Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Cosmi

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Circulation. Heart Failure|May 1, 2015
Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkersFranco Cosmi, Paola Di Giulio, Serge Masson, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Cardiovascular Diabetology|August 10, 2021
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trialJob A J Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, et al.
Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology|March 23, 2026
Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEinging (HOMAGE) randomized trialInês Aguiar-Neves, Sílvia O Diaz, João Pedro Ferreira, et al.
European Journal of Heart Failure|February 24, 2022
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trialJoão Pedro Ferreira, Job A J Verdonschot, Nicolas Girerd, et al.
Medcomm|February 20, 2026
Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma ProteomicsSusana Ravassa, Nicolas Girerd, Frank Edelman, et al.
ESC Heart Failure|November 8, 2023
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trialDiogo Santos-Ferreira, Sílvia O Diaz, João Pedro Ferreira, et al.
European Journal of Heart Failure|July 5, 2019
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fractionLi Shen, Rasmus Rørth, Deborah Cosmi, et al.
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Circulation. Heart Failure|May 1, 2015
Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkersFranco Cosmi, Paola Di Giulio, Serge Masson, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Cardiovascular Diabetology|August 10, 2021
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trialJob A J Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, et al.
Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology|March 23, 2026
Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEinging (HOMAGE) randomized trialInês Aguiar-Neves, Sílvia O Diaz, João Pedro Ferreira, et al.
European Journal of Heart Failure|February 24, 2022
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trialJoão Pedro Ferreira, Job A J Verdonschot, Nicolas Girerd, et al.
Medcomm|February 20, 2026
Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma ProteomicsSusana Ravassa, Nicolas Girerd, Frank Edelman, et al.
ESC Heart Failure|November 8, 2023
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trialDiogo Santos-Ferreira, Sílvia O Diaz, João Pedro Ferreira, et al.
European Journal of Heart Failure|July 5, 2019
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fractionLi Shen, Rasmus Rørth, Deborah Cosmi, et al.
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
Pageof 5